Mission Patent-Cliff Exposure & CMS Drug Spending Portfolio

Mission (US): 9 reconciled FDA prescription therapies, $812K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies9
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$812K
2024 Medicare Part D Spend$54K
2024 Medicaid Spend$757K
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel